Risk scores are statistical indicators based on prescribing patterns compared to specialty peers. They are NOT allegations of fraud, misconduct, or improper care. Many legitimate medical reasons can explain outlier prescribing.
Read our methodology →Risk Flags
Risk indicators are statistical patterns, not allegations. Learn more
8,724
Total Claims
$860K
Drug Cost
183
Beneficiaries
$4,699
Cost/Patient
Risk Score Breakdown 26/100
Score components are additive. Read full methodology
Peer Comparison vs. 106,889 Family Practice providers
-87%
Opioid rate vs peers
0.3% vs 2.6% avg
+340%
Cost per patient vs peers
$4,699 vs $1,068 avg
+71%
Brand preference vs peers
15.4% vs 9.0% avg
⚠️ Opioid + Benzodiazepine Co-Prescriber
This provider prescribes both opioids and benzodiazepines. The FDA has issued a Black Box Warning about the life-threatening risks of concurrent use.
Opioid Prescribing
0.3%
Opioid Rate
29
Opioid Claims
$627
Opioid Cost
—
Long-Acting Rate
Brand vs Generic
Brand: 1,333 claims · $697K
Generic: 7,320 claims · $158K
Top Prescribed Drugs
| Drug (Generic) | Claims | Cost |
|---|---|---|
| Apixaban | 252 | $93K |
| Dulaglutide | 80 | $85K |
| Empagliflozin | 148 | $85K |
| Icosapent Ethyl | 128 | $46K |
| Tirzepatide | 31 | $40K |
| Dapagliflozin Propanediol | 79 | $35K |
| Exenatide Microspheres | 29 | $25K |
| Mirabegron | 49 | $23K |
| Linaclotide | 32 | $17K |
| Sacubitril/Valsartan | 25 | $17K |
| Evolocumab | 16 | $16K |
| Rivaroxaban | 21 | $15K |
| Insulin Detemir | 29 | $14K |
| Linagliptin | 38 | $14K |
| Insulin Degludec | 18 | $12K |
Prescribing Profile
Patient Profile
76
Avg Age
54%
Female
1.15
Avg Risk Score
Explore More
Data from CMS Medicare Part D Prescriber Public Use File, 2023. Risk scores are statistical indicators, not allegations.Methodology · About